Recording of non-operating expenses and extraordinary losses
Carna Biosciences,Inc. (consolidated)
Stock acquisition rights issued to promote the development of docirbrutinib (AS-1763), First Series Unsecured Convertible Bonds with Stock Acquisition Rights, dollar-denominated liabilities, and assets for which indications of impairment had been identified
Interest expense arose from the amortization of issue discounts arising upon the issuance of convertible bonds with stock acquisition rights and bonds, as well as interest on convertible bonds with stock acquisition rights. Stock acquisition rights issuance costs arose from the issuance of stock acquisition rights to promote the development of docirbrutinib (AS-1763). Foreign exchange losses arose from the remeasurement of dollar-denominated liabilities due to fluctuations in foreign exchange rates and losses arising upon settlement, among other items. Losses on redemption of bonds arose from the repurchase and cancellation of the First Series Unsecured Convertible Bonds with Stock Acquisition Rights. Impairment losses arose from reducing assets for which indications of impairment had been identified to their recoverable amounts.
Interest expense of ¥13.186 million (non-operating expense), stock acquisition rights issuance costs of ¥11.249 million (non-operating expense), foreign exchange losses of ¥7.400 million (non-operating expense), losses on redemption of bonds of ¥20.138 million (extraordinary loss), and impairment losses of ¥3.006 million (extraordinary loss)
First quarter of the fiscal year ending December 2026
| Item | Details |
|---|---|
| Event name | Recording of non-operating expenses and extraordinary losses |
| Date of occurrence | 17 February 2026 (issuance of stock acquisition rights and repurchase and cancellation of the First Series Unsecured Convertible Bonds with Stock Acquisition Rights). The other items were recorded in the first quarter of the fiscal year ending December 2026. |
| Subject Entity | Carna Biosciences,Inc. (consolidated) |
| Target Locations / Products | Stock acquisition rights issued to promote the development of docirbrutinib (AS-1763), First Series Unsecured Convertible Bonds with Stock Acquisition Rights, dollar-denominated liabilities, and assets for which indications of impairment had been identified |
| Cause | Interest expense arose from the amortization of issue discounts arising upon the issuance of convertible bonds with stock acquisition rights and bonds, as well as interest on convertible bonds with stock acquisition rights. Stock acquisition rights issuance costs arose from the issuance of stock acquisition rights to promote the development of docirbrutinib (AS-1763). Foreign exchange losses arose from the remeasurement of dollar-denominated liabilities due to fluctuations in foreign exchange rates and losses arising upon settlement, among other items. Losses on redemption of bonds arose from the repurchase and cancellation of the First Series Unsecured Convertible Bonds with Stock Acquisition Rights. Impairment losses arose from reducing assets for which indications of impairment had been identified to their recoverable amounts. |
| Amount of Impact on Business Performance | Interest expense of ¥13.186 million (non-operating expense), stock acquisition rights issuance costs of ¥11.249 million (non-operating expense), foreign exchange losses of ¥7.400 million (non-operating expense), losses on redemption of bonds of ¥20.138 million (extraordinary loss), and impairment losses of ¥3.006 million (extraordinary loss) |
| Accounting period in which recognized | First quarter of the fiscal year ending December 2026 |
Items this document does not state (18)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Interest expense arose mainly from the amortization of issue discounts arising upon the issuance of convertible bonds with stock acquisition rights and bonds, and related items. Stock acquisition rights issuance costs arose from the issuance of stock acquisition rights to promote the development of docirbrutinib (AS-1763). Foreign exchange losses arose mainly from the remeasurement of dollar-denominated liabilities due to fluctuations in foreign exchange rates and losses arising upon settlement. Losses on redemption of bonds arose from the repurchase and cancellation of the First Series Unsecured Convertible Bonds with Stock Acquisition Rights. Impairment losses arose from reducing assets for which indications of impairment had been identified to their recoverable amounts.